These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19196658)

  • 1. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
    Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
    Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
    Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
    Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
    Tai YT; Dillon M; Song W; Leiba M; Li XF; Burger P; Lee AI; Podar K; Hideshima T; Rice AG; van Abbema A; Jesaitis L; Caras I; Law D; Weller E; Xie W; Richardson P; Munshi NC; Mathiot C; Avet-Loiseau H; Afar DE; Anderson KC
    Blood; 2008 Aug; 112(4):1329-37. PubMed ID: 17906076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu.
    Zhang L; Hu Y; Sun CY; Li J; Guo T; Huang J; Chu ZB
    Cancer Sci; 2010 May; 101(5):1117-24. PubMed ID: 20331634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment.
    D'Souza S; Kurihara N; Shiozawa Y; Joseph J; Taichman R; Galson DL; Roodman GD
    Blood; 2012 Feb; 119(8):1888-96. PubMed ID: 22223826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
    Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
    J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
    Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
    Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
    Lin L; Yan F; Zhao D; Lv M; Liang X; Dai H; Qin X; Zhang Y; Hao J; Sun X; Yin Y; Huang X; Zhang J; Lu J; Ge Q
    Oncotarget; 2016 Mar; 7(9):9844-58. PubMed ID: 26848618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.
    Lin L; Cao L; Liu Y; Wang K; Zhang X; Qin X; Zhao D; Hao J; Chang Y; Huang X; Liu B; Zhang J; Lu J; Ge Q
    Leukemia; 2019 Jun; 33(6):1475-1486. PubMed ID: 30573782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
    García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
    J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
    Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
    Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
    Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
    Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.
    Chatterjee M; Stühmer T; Herrmann P; Bommert K; Dörken B; Bargou RC
    Blood; 2004 Dec; 104(12):3712-21. PubMed ID: 15297310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.